ERGOMED

News

London, UK, 23 October 2017

Ergomed’s first-in-class haemostat, PeproStat™, reports positive top-line results and meets key endpoints in Phase II study

–     Highly innovative blood free haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostasis with statistical significance across all surgery types tested

–     PeproStat was seen to be safe with no treatment related SAEs reported and no re-bleeding

–     PeproStat™ demonstrated superiority in…


London, UK, 28 September 2017

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million

and

Placing to raise £2.9 million

  • Acquisition moves Ergomed towards leadership in orphan drug development services
  • PSR’s specialist orphan drug development business will complement Ergomed’s existing strong expertise in this area
  • PSR will expand Ergomed’s services…

London, UK, 27 September 2017

Ergomed Signs First Commercialisation Deal for Haemostatix Products

Boryung Pharmaceutical Co.Ltd licenses PeproStat and ReadyFlow for commercialisation in South Korea

Ergomed to receive an upfront and future milestone payments as well as double-digit share of product sales

Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential

London, UK / Seoul, Republic…


London, UK, 24 July 2017

Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat

– Top line results expected in Q4 2017, six months earlier than anticipated.
– Faster than expected recruitment reflects Ergomed’s strong CRO capabilities.

London, UK – 24 July 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, today announces that recruitment has been completed ahead of schedule in…


London, UK, 21 June 2017

PeproStat Phase IIb study passes recruitment mid-point ahead of schedule – Top line results brought forward to Q4 2017

London, UK – 21 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that its Phase IIb proof-of-concept study for PeproStat, Ergomed’s highly innovative new coagulant, or ‘haemostat’, for intraoperative…


Page 1 of 1712345...10...Last »
Translate »